Table 2.
ClinicalTrials.gov Identifier |
Study title | Cancer types | Intervention | Objective | Status |
---|---|---|---|---|---|
NCT04645680 |
Diet and Immune Effects Trial: DIET—A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy |
Melanoma | Dietary Intervention: Two different diets vary in fiber content | To assess effect of high‐in‐fiber diet on efficacy and toxicity of immunotherapy drugs pembrolizumab or nivolumab | Recruiting |
NCT04866810 | The Effect of Diet and Exercise on Immunotherapy and the Microbiome (EDEN) | Melanoma | Dietary Intervention: A plant‐based, high‐fiber diet and a change for high intensity exercise | To see if nutritional intake and physical activity change the gut microbiota in people with melanoma receiving relatlimab and nivolumab immunotherapy | Not Applicable |
NCT05251389 | FMT to Convert Response to Immunotherapy | Melanoma | Procedure; Fecal Microbial Transplantation | To investigate the influence of FMT on efficacy and toxicity of immunotherapy | Recruiting |
NCT04163289 |
Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation (PERFORM) |
Renal Cell Carcinoma | Drug: Fecal Microbiota Transplant | To study the safety of FMT combination treatment with ipilimumab and nivolumab, and whether reduce incidence of immune‐related toxicities in patients | Recruiting |
NCT04056026 | A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma | Mesothelio‐ma | Biological: Fecal Microbiota Transplant | To see if FMT can increase efficacy of an immunotherapy drug Keytruda | Completed |
NCT04116775 | Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer | Prostate Cancer | Biological: Fecal Microbiota Transplant | To evaluate anticancer effect of FMT in pembrolizumab treatment | Recruiting |
NCT05303493 | Camu‐Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Nonsmall Cell Lung Cancer and Melanoma | Advanced NSCLC Stage IV and Melanoma Stage IV |
Probiotics drug: Camu Camu Capsules |
To evaluate the safety and tolerability of Camu Camu prebiotic in addition to ICI in patients with NSCLC and melanoma | Recruiting |
NCT05220124 | A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma | Bladder Urothelial Carcinoma | Probiotics drug: Live Combined (Bifidobacterium, Lac‐tobacillus, and Enterococcus Capsules) | To evaluate clinical benefits of probiotics in immunotherapy | Recruiting |
NCT04699721 | Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC | Nonsmall Cell Lung Cancer Stage III |
Probiotics drug: Bifidobacterium trifidum live powder |
To evaluate safety and effect of neoadjuvant chemotherapy and immunotherapy combined with probiotics | Recruiting |
Abbreviations: CAR‐T, chimeric antigen receptor T‐cell; CTLA‐4, cytotoxic T lymphocyte‐associated antigen 4; DC, dendritic cell; GI cancer, gastrointestinal cancer; ICI, immune checkpoint inhibitor; NSCLC, nonsmall cell lung cancer; PD‐1, programmed cell death protein 1; PD‐L1, programmed cell death ligand 1; RCC, renal cell cancer; SCFAs, short‐chain fatty acids; TME, tumor microenvironment.